Marinus
Pre-Approval PRO BETAStale Activity
No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 3/1/2024
Pipeline by Phase
Therapeutic Focus
Clinical Trials (17)
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
Started: 5/16/2022
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
Started: 4/1/2022
To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)
Started: 3/1/2024
A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures
Started: 2/1/2015
Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder
Started: 6/30/2018
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
Started: 10/1/2013
Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)
Started: 4/1/2023
A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression
Started: 12/28/2017
A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression
Started: 6/27/2017
Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)
Started: 5/17/2019
Ganaxolone Treatment in Children With Fragile X Syndrome
Started: 11/1/2012
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
Started: 4/8/2020
Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies
Started: 11/6/2015
Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
Started: 2/19/2018
A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
Started: 10/1/2009